A two-part randomized placebo controlled double blind multicenter Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC) (GLISTEN)

Brief description of study

The purpose of this study is to further test an investigational drug called linerixibat (also referred to as GSK2330672) for the treatment of cholestatic pruritus in individuals with primary biliary cholangitis (PBC). Linerixibat is not FDA-approved for doctors to prescribe for patients. It works in the digestive system by blocking bile from reentering the blood, and stops it from building up, as it causes the bile to be removed in stools (poo) instead. The drug is investigational because it is being tested in research studies like this one.


Clinical Study Identifier: s21-00634
Principal Investigator: Ira M. Jacobson.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.